Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Treasury Shares (2019 - 2025)

Keros Therapeutics' Treasury Shares history spans 3 years, with the latest figure at $21.1 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $384.6 million; the TTM value through Dec 2025 reached $384.6 million, changed N/A, while the annual FY2025 figure was $384.6 million, N/A changed from the prior year.
  • Treasury Shares reached $384.6 million in Q4 2025 per KROS's latest filing.
  • In the past five years, Treasury Shares ranged from a high of $21.1 million in Q4 2025 to a low of $721700.0 in Q3 2025.